Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2010 Mar;11(3):230-8.
doi: 10.1016/j.jpain.2009.07.007. Epub 2009 Nov 27.

A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment

Barbara Rakel  1 , Nicholas Cooper, Heather J Adams, Bryan R Messer, Laura A Frey Law, Douglas R Dannen, Carrie A Miller, Anya C Polehna, Rachelle C Ruggle, Carol G T Vance, Deirdre M Walsh, Kathleen A Sluka
Affiliations
Randomized Controlled Trial

A new transient sham TENS device allows for investigator blinding while delivering a true placebo treatment

Barbara Rakel et al. J Pain. 2010 Mar.

Abstract

This study compared a new transient sham transcutaneous electrical nerve stimulation (TENS) that delivers current for 45 seconds to an inactive sham and active TENS to determine the degree of blinding and influence on pain reduction. Pressure-pain thresholds (PPT), heat-pain thresholds (HPT), and pain intensities to tonic heat and pressure were measured in 69 healthy adults before and after randomization. Allocation investigators and subjects were asked to identify the treatment administered. The transient sham blinded investigators 100% of the time and 40% of subjects compared to the inactive sham that blinded investigators 0% of the time and 21% of subjects. Investigators and subjects were blinded only 7% and 13% of the time, respectively, with active TENS. Neither placebo treatment resulted in significant changes in PPT, HPT, or pain intensities. Subjects using higher active TENS amplitudes (> or =17 mAs) had significantly higher PPTs and lower pain intensities to tonic pressure than subjects using lower amplitudes (<17 mAs). HPTs and pain intensities to tonic heat were not significantly changed. The transient TENS completely blinds investigators to treatment and does not reduce pain, thereby providing a true placebo treatment.

Perspective: This article presents the benefits of a new transient sham TENS device for use in prospective, randomized, clinical trials. This device facilitates blinding of subjects and investigators to eliminate expectation bias and determine the true efficacy of TENS for use in clinical populations.

PubMed Disclaimer

Figures

Figure 1
Figure 1
CONSORT trail flow-chart.
Figure 2
Figure 2
Pressure temporal summation measurement during TENS application. Pressure device includes a pressure transducer and a lever with a movable weight to grade the force delivered. The pressure stimulus is delivered through a 1 cm2 probe over the extensor muscle mass.
Figure 3
Figure 3
Percent change from baseline to after treatment for: A) heat pain thresholds; and B) pressure pain thresholds for each group (Active TENS, Inactive Placebo TENS, and Transient Placebo TENS.
Figure 4
Figure 4
Temporal summation to pressure and heat stimuli. A) Pressure pain intensity scores pre and post treatment for each group from 0–120 seconds; B) Average pressure pain intensity scores pre and post treatment for each group; C) Heat pain intensity scores pre and post treatment for each group from 0–120 seconds; D) Average heat pain intensity scores pre and post treatment for each group. A=Active TENS; IP=Inactive Placebo TENS; TP=Transient Placebo TENS.
Figure 5
Figure 5
A) Scatter plot and correlation between percent change in Pressure Pain Threshold (PPT) and TENS pulse amplitudes; B) percent change in PPT for low (0–16mA) and high (17–25mA) TENS pulse amplitudes; C) scatter plot and correlation between change in average pain intensity during temporal summation and TENS pulse amplitudes; D) change in average pain intensity scores during pressure temporal summation and low (0–16mA) and high (17–25mA) TENS pulse amplitudes. Those receiving higher TENS pulse amplitudes in the active TENS group (17–25mA; N = 17), had a significant increase in PPT compared to those receiving lower pulse amplitudes (< 17mA; N = 13)(F1,29 = 9.8, p = 0.004).
See this image and copyright information in PMC

References

    1. Aarskog R, Johnson MI, Demmink JH, Lofthus A, Iversen V, Lopes-Martins R, Joensen J, Bjordal JM. Is mechanical pain threshold after transcutaneous electrical nerve stimulation (TENS) increased locally and unilaterally? A randomized placebo-controlled trial in healthy subjects. Physiother Res Int . 2007;12(Suppl 4):251–263. - PubMed
    1. Agency for Health Care Policy and Research: Agency for Health Care Policy and Research. Acute pain management: Guideline technical report. 1995;1:95–0034.
    1. Bialosky JE, Bishop MD, Robinson ME, Barabas JA, George SZ. The influence of expectation on spinal manipulation induced hypoalgesia: an experimental study in normal subjects. BMC Musculoskelet Disord. 2008;9:19. - PMC - PubMed
    1. Bjerring P, Arendt-Nielsen L. Depth and duration of skin analgesia to needle insertion after topical application of EMLA cream. Br J Anaesth . 1990;64(Suppl 2):173–177. - PubMed
    1. Bjordal JM, Johnson MI, Ljunggreen AE. Transcutaneous electrical nerve stimulation (TENS) can reduce postoperative analgesic consumption. A meta-analysis with assessment of optimal treatment parameters for postoperative pain. Eur J Pain . 2003;7(Suppl 2):181–188. - PubMed

Publication types